ChemComm
Communication
stabilization effects. Furthermore, we have proven that the
absolute configuration of the S = NTs chiral center dominates
the backbone peptides’ secondary structure. Namely, the B
diastereomers with longer retention time in HPLC spectra
showed better helical contents in H2O while A diastereomers
appeared as random coils. CD and 2D NMR experiments
provided strong evidence to support the secondary structure
determination. This new stapling methodology presented good
tolerance to different residues, including glycine. Notably, this
novel helicity-induced method showed good thermal stability,
in guanidineÁHCl denaturation as well as serum digestion. This
discovery enriches the toolbox of peptide stabilization and
helps in further understanding the correlation between the
in-tether chiral center and the backbone peptides’ secondary
structures, and it also provides one valuable modification site
for further applications.
We acknowledge financial support from the National Natural
Science Foundation of China (Grant 21102007, 31300600 and
21372023), MOST 2015DFA31590, MOST 2013CB911500, the
Shenzhen Science and Technology Innovation Committee
(KQCX20130627103353535, SGLH20120928095602764, ZDSY2013-
0331145112855 and JSGG20140519105550503) and the Shenzhen
Peacock Program (KQTD201103). We thank the Beijing NMR
Center at Peking University for their help.
Fig. 4 (A) CD spectrum comparison between L-peptide 10B and D-analog
15B. (B) The absorption change trend of the CD spectrum in the neutralization
titration experiment. Peptide 15B solution was titrated into 10B solution slowly
until 15B was excessive. (C) Full CD spectra of 3B at different temperatures
from 25 1C to 70 1C. (D) Molar ellipticity at 215 nm of 3B at different
temperatures from 25 1C to 70 1C. (E) Molar ellipticity at 215 nm of 12B under
the condition of increasing guanidineÁHCl at 25 1C. (F) In vitro serum digestion
assay of peptide 11B and its linear analog.
Notes and references
1 D. P. Ryan and J. M. Matthews, Curr. Opin. Struct. Biol., 2005, 15, 441.
2 (a) D. J. Barlow and J. M. Thornton, J. Mol. Biol., 1988, 201, 601;
(b) D. P. Fairlie, M. L. West and A. K. Wong, Curr. Med. Chem., 1998,
5, 29.
3 (a) M. Pellegrini, M. Royo, M. Chorev and D. F. Mierke, J. Pept. Res.,
1997, 49, 404; (b) D. Y. Jackson, D. S. King, S. Singh and P. G. Schultz,
J. Am. Chem. Soc., 1991, 113, 9391; (c) J. H. B. Pease, R. W. Storrs and
D. E. Wemmer, Proc. Natl. Acad. Sci. U. S. A., 1990, 87, 5643.
4 (a) J. W. Taylor, Biopolymers, 2002, 66, 49; (b) N. E. Shepherd,
H. N. Hoang, G. Abbenante and D. P. Fairlie, J. Am. Chem. Soc.,
2005, 127, 2974; (c) G. Osapay and J. W. Taylor, J. Am. Chem. Soc.,
1992, 114, 6966.
5 (a) H. E. Blackwell and R. H. Grubbs, Angew. Chem., Int. Ed., 1998,
37, 3281; (b) C. E. Schafmeister, J. Po and G. L. Verdine, J. Am. Chem.
Soc., 2000, 122, 5891; (c) H. E. Blackwell, J. D. Sadowsky, R. J.
Howard, J. N. Sampson, J. A. Chao, W. E. Steinmetz and R. H. Grubbs,
J. Org. Chem., 2001, 66, 5291; (d) F. Bernal, M. Wade, M. Godes, T. N.
Davis, D. G. Whitehead, A. L. Kung and L. D. Walensky, Cancer Cell, 2010,
18, 411; (e) F. Bernal, A. F. Tyler, S. J. Korsmeyer, L. D. Walensky and
G. L. Verdine, J. Am. Chem. Soc., 2007, 129, 2457.
6 C. M. Haney, M. T. Loch and W. S. Horne, Chem. Commun., 2011,
47, 10915.
7 A. M. Spokoyny, Y. K. Zou, J. J. Ling, H. T. Yu, Y. S. Lin and B. L.
Pentelute, J. Am. Chem. Soc., 2013, 135, 5946.
8 Y. H. Lau, P. Andrade, N. Skold, G. J. Mckenzie, C. Verma, D. P. Lane
and D. R. Spring, Org. Biomol. Chem., 2014, 12, 4074.
9 T. E. Speltz, S. W. Fanning, C. G. Mayne, E. Tajkhorshid, G. L. Greene
and T. W. Moore, Angew. Chem., Int. Ed., 2016, 55, 4252.
10 K. Hu, H. Geng, Q. Z. Zhang, Q. S. Liu, M. S. Xie, H. C. Lin, F. Jiang,
T. Wang, Y. D. Wu and Z. G. Li, Angew. Chem., Int. Ed., 2016, 55, 8013.
11 For details of synthesis of sulfilimines, see (a) F. Collet, R. H. Dodd
and P. Dauban, Org. Lett., 2008, 10, 5473; (b) O. G. Mancheno and
C. Bolm, Org. Lett., 2006, 8, 2349; (c) O. G. Mancheno, J. Dallimore,
A. Plant and C. Bolm, Org. Lett., 2009, 11, 2429; (d) G. Y. Cho and
C. Bolm, Org. Lett., 2005, 7, 4983; (e) A. L. Marzinzik and K. B.
Sharpless, J. Org. Chem., 2001, 66, 594.
denaturants (Fig. 4). CD measurements of 3B in H2O from 25 1C
to 70 1C showed that 3B maintained a well-defined a-helix even
at 70 1C (Fig. 4C). A gradual increase in molar ellipticity was
observed at 215 nm when the temperature was increased from
25 1C to 70 1C, which indicated that the a-helix content
decreased in 3B (Fig. 4D). Despite some a-helix unwinding,
over 60% a-helicity was preserved even at 70 1C, which suggested
that the sulfilimine chiral center-induced a-helicity was thermally
stable. Pentapeptide 12B was used for chemical denaturation under
the condition of increasing guanidineÁHCl from 0 to 7 M. The
molar ellipticity at 215 nm of 12B remained almost unchanged with
increasing guanidineÁHCl, suggesting that the a-helical conforma-
tion of 12B was stable even in the presence of high concentration of
guanidineÁHCl (Fig. 4E). Besides, the in vitro serum stability assay
showed that more than 90% of the helical peptide 11B with the
sulfilimine chiral center remained intact after 10 hours while over
50% degradation of its linear analog, termed Ac-S5ALAC(SH)-NH2,
was observed (Fig. 4F). Thus, peptide 11B with enhanced helicity
induced by the sulfilimine chiral center showed better proteolytic
resistance.
In summary, we have demonstrated a novel and effective
helix-stabilizing strategy by introducing a precisely positioned
S = NTs chiral center via chloramine-T oxidation. The tether
length and S = NTs positions were screened for the best helix
This journal is ©The Royal Society of Chemistry 2016
Chem. Commun.